作　　者： (袁平）; (梁岩）; (饶绍奇）;

机构地区： 广东医科大学

出　　处： 《中华临床医师杂志（电子版）》 2017年第10期1816-1820,共5页

摘　　要： LCZ696是第一个血管紧张素受体和脑啡肽酶联合抑制剂,具有抑制脑啡肽酶和肾素-血管紧张素-醛固酮系统(RAAS)的双重作用,脑啡肽酶受抑制后,增加血浆利钠肽的水平,利钠肽具有利钠,调节钠水平衡等作用,抑制RAAS,抑制交感神经的活性等作用。RAAS与心力衰竭、高血压等心血管疾病的发生发展密切相关。多项研究表明LCZ696对于心力衰竭、高血压、心肌梗死有显著的临床疗效。现就LCZ696在心血管疾病中的研究进展及安全性作一综述。 LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor. It has a dual inhibition of the renin angiotensin aldosterone system(RAAS) and enkephalinase. Inhibition of neprilysin increases the levels of natriuretic peptides, that contributes to sodium retention. Inhibition of RAAS and sympathetic nervous system. The occurrence and development of cardiovascular diseases, such as heart failure, hypertension and so on, are closely related to RAAS. The treatment of LCZ696 in hypertension and heart failure results in clinical benefits. The review summarized the mechanism, clinical application safety, and tolerability of LCZ696 on its outcomes in trial.

关 键 词： 高血压 心力衰竭 心肌梗死 血管紧张素受体 脑啡肽酶抑制剂